Genitourinary Cancers

Bradley McGregor, MD, discusses the evolving treatment landscape of renal cell carcinoma.

Guru P. Sonpavde, MD, discusses the need for phase 3 data evaluating frontline pembrolizumab or atezolizumab in bladder cancer.

Steven Lee Chang, MD, discusses the impact of the coronavirus disease 2019 on the surgical management of patients with genitourinary cancers.

A supplemental new drug application has been submitted to the FDA for the combination of cabozantinib and nivolumab as a treatment for patients with advanced renal cell carcinoma.

Toni K. Choueiri, MD, discusses the novel coronavirus disease, which continues to impact the care of patients with metastatic renal cell carcinoma and other cancers in a multitude of ways.

Praful K. Ravi, MD, discusses the evolving treatment landscape of advanced bladder cancer.

Eric Jonasch, MD, discusses the role of inhibiting hypoxia-inducible factor-2α in Von Hippel-Lindau disease–associated renal cell carcinoma.

Bradley McGregor, MD, discusses some of the recent approaches that have emerged in bladder cancer and renal cell carcinoma, as well as anticipated developments in each field.

The FDA has granted a priority review designation to a supplemental biologics license application for a new 4-week, fixed-dose regimen as treatment in approved indications of non–small cell lung cancer and bladder cancer.

Guru P. Sonpavde, MD, discusses the utility of combining anti-VEGF and anti–PD-1 agents in metastatic urothelial carcinoma.

Rana R. McKay, MD, discusses the role of age and gender in advanced renal cell carcinoma outcomes. 

The combination of ARID1A mutations and the immune signaling protein CXCL13 proved to be predictive of clinical response and prolonged survival after treatment with checkpoint inhibitors in patients with metastatic urothelial carcinoma.

Scott S. Tykodi, MD, PhD, provides background to the phase 2 KEYNOTE-427 trial with pembrolizumab in renal cell carcinoma.